Australian Institute of Health and Welfare (2022) Alcohol, tobacco & other drugs in Australia, AIHW, Australian Government, accessed 01 February 2023.
Australian Institute of Health and Welfare. (2022). Alcohol, tobacco & other drugs in Australia. Retrieved from https://www.aihw.gov.au/reports/alcohol/alcohol-tobacco-other-drugs-australia
Alcohol, tobacco & other drugs in Australia. Australian Institute of Health and Welfare, 14 December 2022, https://www.aihw.gov.au/reports/alcohol/alcohol-tobacco-other-drugs-australia
Australian Institute of Health and Welfare. Alcohol, tobacco & other drugs in Australia [Internet]. Canberra: Australian Institute of Health and Welfare, 2022 [cited 2023 Feb. 1]. Available from: https://www.aihw.gov.au/reports/alcohol/alcohol-tobacco-other-drugs-australia
Australian Institute of Health and Welfare (AIHW) 2022, Alcohol, tobacco & other drugs in Australia, viewed 1 February 2023, https://www.aihw.gov.au/reports/alcohol/alcohol-tobacco-other-drugs-australia
Get citations as an Endnote file:
On this page:
Stimulants are a group of drugs that produce stimulatory effects by increasing nerve transmission in the brain and body (Nielsen & Gisev 2017). Included in this group are:
Recent consumption of meth/amphetamine decreased among people aged 14 and over from 3.4% in 2001 to 1.3% in 2019
Recent cocaine use increased significantly between 2016 (2.5%) and 2019 (4.2%) across all age groups, except 14–19 year olds
Australia had the highest average total stimulant consumption when compared with 28 countries across Europe, Oceania, and South Africa
Methamphetamine accounted for 8.2% of all drug-related hospitalisations in 2020–21 (12,400 hospitalisations), down from 10% in 2019–20 (14,100 hospitalisations).
There has been a rapid increase in the number of deaths involving methamphetamine and other stimulants, with the death rate in 2020 4 times higher than that in 2000 (2.1 deaths compared with 0.5 deaths per 100,000 population, respectively).
In 2020–21, amphetamines were the second most common principal drug of concern in closed treatment episodes provided for clients’ own drug use (24%)
View the Meth/amphetamine and other stimulants in Australia fact sheet >
The focus in this section is on the illicit use of meth/amphetamine and other stimulants (Box STIM1).
Data sources on methamphetamine, amphetamine and other psychostimulants contain a variety of terms; in some instances these terms cover similar, but not the same range of drugs. This can be confusing when interpreting results across different data sources.
Below is a description of each term used in these data sources and the types of drugs they encompass:
People who regularly use illicit drugs report that methamphetamine and other stimulants are easy to obtain in Australia.
Findings from the Illicit Drug Reporting System (IDRS) show that people who inject drugs commonly report it is ‘easy’ or ‘very easy’ to obtain methamphetamine and other stimulants. Specifically in 2022:
Similarly, data from the 2022 Ecstasy and Related Drugs Reporting System (EDRS) show that most people who use ecstasy and other stimulants report that methamphetamine, ecstasy and cocaine are ‘easy’ or ‘very easy’ to obtain (Sutherland et al. 2022a). Findings show that:
Data collection for 2022 took place from April–July for the EDRS and May–July for the IDRS. Due to COVID-19 restrictions being imposed in various jurisdictions during data collection periods for both the IDRS and the EDRS, interviews in 2020, 2021 and 2022 were delivered face-to-face as well as via telephone. This change in methodology should be considered when comparing data from the 2020, 2021 and 2022 samples relative to previous years.
The Australian Criminal Intelligence Commission (ACIC) collects national illicit drug seizure data annually from federal, state and territory police services, including the number and weight of seizures to inform the Illicit Drug Data Report (IDDR). According to the latest IDDR, in 2019–20, around one-third of national illicit drug seizures (39,204 or 32%) were amphetamine-type stimulants (ATS) (including MDMA).
The number of national ATS seizures has increased by 250% over the last decade, with 39,204 seizures in 2019–20, up from 11,212 in 2010–11. In 2019–20, ATS accounted for 33% of the total weight of illicit drugs seized nationally. The total weight of ATS seized nationally has increased 1,175% over the last decade, from 1,009 kilograms in 2010–11 to a record 12,865 kilograms in 2019–20.
The record 34,113 national amphetamines seizures in 2019–20 weighed a record 9,408 kilograms and accounted for 87% of the number and 73% of the weight of ATS seized nationally this reporting period (ACIC 2021a). Research (ACIC 2019b) has shown the impact of seizures on consumption—see Supply reduction – Prohibited substances (ACIC 2021a; tables S1.18 and S1.19).
In 2019–20, there were 1,377 amphetamine-type stimulant (excluding MDMA) detections at the Australian border, weighing 5,272 kilograms. The number of MDMA (ecstasy) detections at the Australian border was 2,308 in 2019–20, while the weight of MDMA detected was 1,291 kilograms. The number of national MDMA seizures was 4,981 in 2019–20, and the total weight of MDMA seized nationally was 3,214 kilograms, accounting for 13% of the number and 25% of the weight of ATS seized nationally (ACIC 2021a).
Over the last decade, the number of cocaine detections at the Australian border increased by 447%, from 486 in 2010–11 to 2,660 in 2019–20. The weight of cocaine detected has increased by 9%, from 701 kilograms in 2010–11 to 763 kilograms in 2019–20 (ACIC 2021a).
The number of national cocaine seizures has increased by 372% over the last decade, from 1,217 in 2010–11 to a record 5,750 in 2019–20. The weight of cocaine seized nationally increased by 138% over the same period, from 662 kilograms in 2010–11 to 1,573 kilograms in 2019–20 (ACIC 2021a).
For related content on meth/amphetamine and other stimulant consumption by region, see also:
There are differences in trends and patterns of consumption in Australia according to the type of stimulant used.
Self-reported data on meth/amphetamine consumption in the general Australian population has been declining since it peaked at 3.4% in 2001. There was a substantial decrease in the recent use of meth/amphetamine among people aged 20–29 (from 11.2% in 2001 to 2.4% in 2019), however, there were slight increases for people aged 40 and over (AIHW 2020, Table 4.72). It is possible that self-report surveys underestimate the true extent of meth/amphetamine use, particularly in the context of the stigmas that exist around its consumption (AIHW 2020).
In 2013, ‘crystal/ice’ replaced powder as the main form of meth/amphetamine used in the previous 12 months. In 2019, this trend continued with 50% of people who used meth/amphetamine reporting that crystal/ice was the main form used in the previous 12 months (AIHW 2020). While overall recent meth/amphetamine use declined between 2013 and 2019, the proportion using crystal/ice remained relatively stable (AIHW 2020).
Participants in the EDRS reported a decrease in the use of crystal methamphetamine in the preceding 6 months (29% in 2012 to 18% in 2022) (Sutherland et al. 2022a, Figure 16).
The figure shows the proportion of people who recently used meth/amphetamine in the last 12 months by age group from 2001 to 2019. Between 2001 and 2019, there were decreases for age groups of 14–19, 20–29, and 14 and over who had recently used meth/amphetamine. Over the same period, the proportion of people aged 30–39, and 50 and over who recently used meth/amphetamine remained stable. In 2019, people aged 20–29 (2.4%) and 30–39 (2.0%) were most likely to have recently used meth/amphetamine.
The 2019 NDSHS found:
In 2022 ecstasy and cannabis were the most common reported drug of choice for participants of the EDRS who regularly use ecstasy and other stimulants (Sutherland et al. 2022a, Figure 1). EDRS participants indicated that when the past 6 months was compared with the previous year:
There was a significant increase in lifetime use of cocaine between 2016 (9%) and 2019 (11.2%) (AIHW 2020, Table 4.2). This was driven largely by increases for people aged 20–29 (from 13.2% to 19.5%), 40–49 (from 12.0% to 15.3%) and 50 and older (3.4% to 4.3%) (AIHW 2020).
For participants of the EDRS, cocaine was the third most commonly used stimulant drug (after ecstasy and cannabis) with 79% reporting past 6 month use in 2022, remaining stable relative to 2021 (80%) (Sutherland et al. 2022a).
Data from the National Wastewater Drug Monitoring Program (NWDMP) show that the population-weighted average consumption of stimulant drugs varies based on drug type and geographic area.
Methylamphetamine continued to have the highest population-weighted average consumption of any illicit drug monitored by the program (ACIC 2022b). Data from Report 17 of the NWDMP indicate that nationally, in April 2022 compared to December 2021:
The estimated weight of methylamphetamine consumed increased from 8,405 kilograms in 2016–17 to 11,516 kilograms in 2018–19, before declining to 8,838 kilograms in 2020–21 (ACIC 2022a, Figure STIM2).
For state and territory data, see the National Wastewater Drug Monitoring Program reports.
(a) 'Average consumption' refers to estimated population-weighted average consumption.
Note: Report 15 covers 57% of the Australian population (58 wastewater treatment sites), Report 17 covers 56% of the Australian population (57 wastewater treatment sites).
Source: AIHW, adapted from ACIC 2022a and ACIC 2022b.
MDMA consumption is low across the country, relative to other illicit drugs and has been declining for the past 2 years. The estimated weight of MDMA consumed annually in Australia steadily increased from 1,162 kilograms in 2017–18 to 2,630 kilograms in 2019–20 before dropping to 1,231 kilograms in 2020–21 (ACIC 2022a). Data from Report 16 of the NWDMP indicate that nationally:
For state and territory data, see the National Wastewater Drug Monitoring Program reports.
Cocaine consumption in Australia steadily increased from 3,057 kilograms in 2016–17 to 5,675 kilograms in 2019–20 before declining to 4,711 kilograms in 2020–21 (ACIC 2022a). Data from Report 16 of the NWDMP indicate that:
It is important to note that the NWDMP does not measure all drug types and cannabis (the drug found to have the highest self-reported level of recent consumption in the 2019 NDSHS) was not included in the comparison of the highest consumed drugs monitored by the program because a reliable dose figure is not available. For further information, see Box HARM2 and Data quality for the National Wastewater Drug Monitoring Program.
Data from the 2019 NDSHS showed that:
This figure shows the proportion of recent cocaine use for people aged 14 and over by remoteness area for 2010, 2013, 2016 and 2019. Recent cocaine use trends differed across all 4 remoteness areas between 2010 and 2019. In 2019, recent cocaine use was more common in Major cities (5%) than in Outer regional and Remote and very remote areas (1.4% and 1.7%, respectively).
View data tables >
The National Wastewater Drug Monitoring Program (NWDMP) recently examined average stimulant consumption (amphetamine, methylamphetamine, cocaine, and MDMA) in Australia compared with 28 countries across Europe, Oceania, and Asia. In March/April 2021:
When examining each drug type as a proportion of total combined stimulant consumption:
Poly drug use is defined as the use of mixing or taking another illicit or licit drug whilst under the influence of another drug. In 2019, the NDSHS showed that only 8.1% of people who reported using meth/amphetamine in the last 12 months said they did not use any other illicit drug. The most common other drugs concurrently used were cannabis (78%) and cocaine (57%). More than three-quarters exceeded the alcohol single occasion risk guideline at least monthly (76%) and over half (54%) exceeded the lifetime risk guideline (AIHW 2020, Table 1.3).
People who reported recent use of ecstasy and cocaine also reported concurrent use of cannabis (77% and 69%, respectively) and 8 in 10 exceeded the alcohol single occasion risk guideline at least monthly (83% and 82%, respectively).
Data on alcohol and other drug-related ambulance attendances are sourced from the National Ambulance Surveillance System (NASS). Monthly data for 2021are currently available for New South Wales, Victoria, Queensland, Tasmania and the Australian Capital Territory. It should be noted that some data for Tasmania and the Australian Capital Territory have been suppressed due to low numbers. Please see the data quality statement for further information.
In 2021, the proportion of amphetamine-related ambulance attendances where multiple drugs were involved (excluding alcohol) ranged from 33% of attendances in Queensland to 48% of attendances in Victoria (Table S1.10).
For related content on multiple drug involvement see Impacts: Ambulance attendances.
For related content on meth/amphetamine and other stimulant impacts and harms, see also:
The short and long-term effects associated with the use of methamphetamine and other stimulants are provided in Table STIM1.
Methamphetamine (includes powder, base and crystal/ice)
Source: Adapted from ACIC 2019a; Darke, Kaye & Duflou 2017; NSW Ministry of Health 2017.
The Australian Burden of Disease Study, 2018, found that amphetamine use was responsible for 0.7% of the total burden of disease and injuries in Australia in 2018 and 24% of the total burden due to illicit drug use (AIHW 2021b) (Table S2.5).
Of the burden due to amphetamine use, drug use disorder (excluding alcohol) contributed 32%, poisoning 17% and suicide and self-inflicted injuries 5.4%. Other contributors to the burden due to amphetamine use included road traffic injuries–motor vehicle occupants and motorcyclists (3.0% each) (AIHW 2021b).
Cocaine use contributed 0.3% of the total burden of disease and injuries in 2018 and 10.9% of the total burden due to illicit drug use (Table S2.5). Of the burden due to cocaine use, suicide and self-inflicted injuries accounted for 6.4% and drug use disorder (excluding alcohol) 10.6% (AIHW 2021b).
Data on alcohol and other drug-related ambulance attendances are sourced from the National Ambulance Surveillance System (NASS). Monthly data are presented in 2021 for people aged 15 years and over for New South Wales, Victoria, Queensland, Tasmania and the Australian Capital Territory.
In 2021, for amphetamine-related ambulance attendances (including crystal methamphetamine) in these jurisdictions:
In New South Wales, Victoria and Queensland (numbers for Tasmania and the Australian Capital are too small to report):
This figure shows amphetamine-related ambulance attendances in NSW. The highest number of attendances were for males aged 25-34. There is a filter to select state/territory, drug and measure (number of attendances or rate per 100,000 population).
Drug-related hospitalisations are defined as hospitalisations with a principal diagnosis relating to a substance use disorder or direct harm relating to use of selected substances (AIHW 2018).
AIHW analysis of the National Hospital Morbidity Database (NHMD) showed that, among all drug-related hospitalisations in 2020–21:
This represents a rate of 48.4 hospitalisations per 100,000 population for methamphetamine and 7.0 per 100,000 for cocaine (Table S1.13). Around 2 in 3 hospitalisations for cocaine ended with a same-day discharge (67% or 1,200 hospitalisations). By contrast, around 7 in 10 hospitalisations for methamphetamine involved an overnight stay (71% or 8,800) (Table S1.12).
In 2020–21, most hospitalisations occurred in Major cities for both methamphetamine (71% or 8,800 hospitalisations) and cocaine (94% or 1,700 hospitalisations) (Table S1.14).
In the 6 years to 2020–21:
The finding for cocaine is consistent with analysis of the NHMD by the National Drug and Alcohol Research Centre (NDARC). This analysis showed that, accounting for population growth and ageing, the rate of cocaine-related hospitalisations increased almost 6-fold between 2010–11 (0.8 per 100,000 population) and 2018–19 (4.5 per 100,000 population). A significant increased was also observed between 2019–20 (4.8 per 100,000 population) and 2020–21 (6.7 per 100,000 population) (Chrzanowska et al. 2022a).
Drug-induced deaths are determined by toxicology and pathology reports and are defined as those deaths that can be directly attributable to drug use. This includes deaths due to acute toxicity (for example, drug overdose) and chronic use (for example, drug-induced cardiac conditions) (ABS 2021).
The rate of drug-induced deaths related to methamphetamine and other stimulants has increased rapidly in recent years.
See also Health impacts: Drug-induced deaths for more information.
The 2020–21 Alcohol and Other Drug Treatment Services in Australia annual report shows that amphetamines were the principal drug of concern in 24% of treatment episodes provided for clients’ own drug use (AIHW 2022).
These are similar proportions to 2019–20 (28% of closed treatment episodes for amphetamines and 1.5% for cocaine and MDMA) (AIHW 2021a).
Data collected for the AODTS NMDS are released twice each year–an Early Insights report in April and a detailed report mid-year.
Data from the AIHW Alcohol and Other Drug Treatment Services National Minimum Data Set (AODTS NMDS) for amphetamines correspond to the Australian Standard Classification of Drugs of Concern (ASCDC) code for the general ‘amphetamines’ classification, in which methamphetamine is a sub-classification. Specific coding for methamphetamine episodes have not previously been available due to the nature of the coding structure. This has improved over time, due to improved workforce training and new system updates (AIHW 2021).
The AODTS NMDS provides information on treatment provided to clients by publicly funded AOD treatment services, including government and non-government organisations. Data from the AODTS NMDS showed that amphetamines were the second most common principal drug of concern in closed treatment episodes provided to clients in 2020–21. Amphetamines were the principal drug of concern in 24% of closed treatment episodes for clients’ own drug use – a similar proportion to 2019–20 (28%). Almost 4 in 5 (79%) amphetamine treatment episodes were for methamphetamine (AIHW 2022).
In 2020–21, where amphetamines were the principal drug of concern:
Source: AIHW 2022, tables Drg.1, SC.11 and Drg.36.
In 2016–17, where the principal drug of concern was amphetamines, the proportion of people living in Regional and remote areas who travelled 1 hour or longer to treatment services was higher than in Major cities (31% compared with 10%) (AIHW 2019).
In 2020–21, ecstasy was the principal drug of concern in less than 1% (0.3%) of closed treatment episodes provided for clients’ own drug use (AIHW 2022, Table Drg.5). Treatment episodes for ecstasy remained relatively stable over the 10-year period to 2020–21.
In 2020–21, where ecstasy was the principal drug of concern:
In 2020–21, cocaine was the principal drug of concern in 1.1% of closed treatment episodes provided for clients’ own drug use (AIHW 2022, Table Drg.5). The proportion of treatment episodes for cocaine has remained low over the 10-year period to 2020–21, increasing from 0.3% of episodes in 2011–12 (AIHW 2022).
In 2020–21, where cocaine was the principal drug of concern:
For related content on at-risk groups, see:
The use of meth/amphetamine and other stimulants can be disproportionately higher for specific population groups.
The NDSHS found that between 2016 and 2019, more people associated meth/amphetamine with a drug problem (46% compared with 49%) and thought it caused the most deaths (19.2% compared with 20%) (AIHW 2020, tables 9.1 & 9.3). Meth/amphetamine was reported to be the drug of most concern to the community by 2 in 5 (40%) people (AIHW 2020, Table 9.5).
In April 2015, the Australian Government established a National Ice Taskforce, to provide advice on the development of a National Ice Action Strategy (NIAS).
The objectives of the NIAS are to ensure that:
ACIC (Australian Criminal Intelligence Commission) 2019. Methylamphetamine supply reduction—measures of effectiveness. Canberra: ACIC. Viewed 14 October 2019.
ACIC 2020. National Wastewater Drug Monitoring Program Report 10. Canberra: ACIC. Viewed 30 June 2020.
ACIC 2021. Illicit Drug Data Report 2019–2020. Canberra: ACIC. Viewed 25 October 2021.
ACIC 2022a. National Wastewater Drug Monitoring Program Report 15. Canberra: ACIC, accessed 21 March 2022.
ACIC 2022b National Wastewater Drug Monitoring Program Report 17. Canberra: ACIC, accessed 3 November 2022.
AIHW (Australian Institute of Health and Welfare) 2018. Drug related hospitalisations. Cat. no. HSE 220. Canberra: AIHW. Viewed 18 August 2021.
AIHW 2019. Alcohol and other drug use in regional and remote Australia: consumption, harms and access to treatment, 2016–17. Cat. no. HSE 212. Canberra: AIHW. Viewed 15 March 2019.
AIHW 2020. National Drug Strategy Household Survey 2019. Drug statistics series no. 32. Cat. no. PHE 270. Canberra: AIHW. Viewed 16 July 2020.
AIHW 2021a. Alcohol and other drug treatment services in Australia annual report. Cat. no. HSE 250. Canberra: AIHW. Viewed 16 July 2021.
AIHW 2021b. Australian Burden of Disease Study: Impact and causes of illness and death in Australia 2018, AIHW, Australian Government. doi:10.25816/5ps1-j259
AIHW 2022. Alcohol and other drug treatment services in Australia annual report. Cat. No. HSE 250. AIHW, Australian Government, accessed 27 July 2022.
Chrzanowska, A, Man, N, Sutherland, R, Degenhardt, L & Peacock, A 2022) Trends in overdose and other drug-induced deaths in Australia, 1997-2020. Sydney: National Drug and Alcohol Research Centre, UNSW Sydney, accessed 23 June 2022.
Chrzanowska A, Man N, Akhurst J, Sutherland R, Degenhardt L & Peacock A 2022a. Trends in drug-related hospitalisations in Australia, 1999–2021. Drug Trends Bulletin Series. Sydney: National Drug and Alcohol Research Centre, UNSW, accessed 2 November 2022.
Darke S, Kaye S & Duflou J 2017. Rates, characteristics and circumstances of methamphetamine-related death in Australia: a national 7-year study. Addiction 112: 2191-2201.
DoH (Department of Health) 2017. National ice action strategy. Canberra: DoH. Viewed 29 November 2017.
Man N, Chrzanowska A, Sutherland R, Degenhardt L & Peacock A 2021. Trends in drug-related hospitalisations in Australia, 1999–2019. Drug Trends Bulletin Series. Sydney: National Drug and Alcohol Research Centre, UNSW. Viewed 13 August 2021.
Nielsen S & Gisev N 2017. Drug pharmacology and pharmacotherapy treatments. In Ritter, King and Lee (eds). Drug use in Australian society. 2nd edn. Oxford University Press.
NSW Ministry of Health 2017. A quick guide to drugs & alcohol, 3rd edn. Sydney: National Drug and Alcohol Research Centre, UNSW. Viewed 24 June 2021.
Peacock A, Uporova J, Karlsson A, Gibbs D, Swanton R, Kelly G et al. 2019. Australian Drug Trends 2019: Key findings from the National Illicit Drug Reporting System (IDRS) Interviews. Sydney: National Drug and Alcohol Research Centre UNSW.
Sutherland R, Karlsson A, King C, Jones F, Uporova J, Price O, Gibbs D, Bruno R, Dietze P, Lenton S, Salom C, Grigg J, Wilson Y, Wilson J, Daly C, Thomas N, Juckel J, Degenhardt L, Farrell M and Peacock A. 2022a. Australian Drug Trends 2022: Key Findings from the National Ecstasy and Related Drugs Reporting System (EDRS) Interviews. Sydney: National Drug and Alcohol Research Centre, UNSW Sydney. Viewed 13 October 2022.
Sutherland R, Uporova J, King C, Jones F, Karlsson A, Gibbs D, Price O, Bruno R, Dietze P, Lenton S, Salom C, Daly C, Thomas N, Juckel J, Agramunt S, Wilson Y, Que Noy W, Wilson J, Degenhardt L, Farrell M and Peacock A. 2022b. Australian Drug Trends 2022: Key Findings from the National Illicit Drug Reporting System (IDRS) Interviews. Sydney: National Drug and Alcohol Research Centre, UNSW Sydney. Viewed 13 October 2022.
We'd love to know any feedback that you have about the AIHW website, its contents or reports.
The browser you are using to browse this website is outdated and some features may not display properly or be accessible to you. Please use a more recent browser for the best user experience.